和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

休市中 04-02 16:08:21

23.560

-0.320

-1.34%

最高24.160	最低23.040	成交量721.90万
今开23.880	昨收23.880	日振幅4.69%
总市值205.44亿	流通市值205.44亿	总股本8.72亿
成交额1.70亿	换手率0.83%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":23.56,"timestamp":1775117301002,"preClose":23.88,"halted":0,"volume":7219000,"delay":0,"changeRate":-0.013400335008375222,"floatShares":872000000,"shares":872000000,"eps":4.075610558986739,"marketStatus":"休市中","change":-0.32,"latestTime":"04-02 16:08:21","open":23.88,"high":24.16,"low":23.04,"amount":169759850,"amplitude":0.046901,"askPrice":23.56,"askSize":29000,"bidPrice":23.52,"bidSize":500,"shortable":3,"etf":0,"ttmEps":4.075610558986739,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":23.88,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":1.1825144460225971,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2624046576","title":"交银国际：4月港股有望筑底企稳 关注AI应用、智能驾驶等","url":"https://stock-news.laohu8.com/highlight/detail?id=2624046576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624046576?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:47","pubTimestamp":1775116050,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，港股3月主要扰动并非来自基本面，而是中东地缘不确定性，在缺乏企稳条件下，指数承压。港股有望从高波动震荡阶段缓步过渡至阶段性筑底企稳。另外，中东地缘不确定性若持续，高油价对内地能源板块仍形成直接盈利支撑，同时黄金受惠全球避险情绪与美元压力，维持战略性高配。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","LU0650527681.SGD","LU0588546209.SGD","IE00B29SXG58.USD","02319","IE00B0169L03.USD","LU0385154629.USD","LU0163747925.USD","BK1589","LU0640798160.USD","IE00B067MR52.USD","LU1048588211.SGD","LU0359201612.USD","IE0008369823.USD","LU1023057109.AUD","LU0072462343.USD","LU1769817096.USD","HK0000320264.USD","IE00B031J352.USD","SG9999002828.SGD","LU0737861699.HKD","LU0594300419.USD","HK0000306685.HKD","LU0320764755.SGD","BK4585","LU0128522157.USD","LU2125910500.SGD","LU0672654166.SGD","LU0173614495.USD","LU2045819591.USD","BK1144","IE0009570106.USD","02525","LU0543330483.HKD","LU1102505929.USD","LU0370786039.SGD","HSAI","LU0228367735.SGD","LU0823426308.USD","LU1051768304.USD","AVGO","IE0032834883.USD","LU0651946864.USD","LU0048580855.USD","BK1237","LU0315179316.USD","LU0228659784.USD","LU0287142896.SGD","LU0326950275.SGD","LU0259732245.USD","LU0106959298.USD","SG9999011746.SGD","00778","LU1224709979.USD","BK1588","LU0029875118.USD","BK4588","IE0031814852.USD","BK1521","HCM","CIADY","LU0823426480.USD","IE00B031HY20.USD","LU1515016050.SGD","BK1587","BK1553","LU0359201885.HKD","LU0348788117.USD","BK1597","BK1147","LU0328353924.USD","BK1256","IE0008368742.USD","300274","LU1439103000.SGD","LU1769817179.HKD","IE00B97KM107.HKD","HK0000306701.USD","BK1191","LU0211977185.USD","LU0307460666.USD","LU0471298777.SGD","LU1102505762.USD","HK0000320223.HKD","00013","LU1115378108.SGD","NVDA","LU0251143458.SGD","BK1098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199960105","title":"和黄医药3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1199960105","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199960105?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:37","pubTimestamp":1775032670,"startTime":"0","endTime":"0","summary":"和黄医药于2026年4月1日披露2026年3月的股份变动月报表。公告显示，截至2026年3月31日，公司法定股本维持在15亿股，面值0.1美元，总额1.5亿美元，较上月底无任何增减变动。公司已发行股份数量维持872,327,620股，与上月底保持一致，期间未发生新增发行、购回或注销行为，也无库藏股变动。公告确认公司目前符合香港联交所关于上市公司公众持股量的要求。公司同时声明，已遵照相关上市规则及适用法律规定履行披露义务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107845235","title":"异动解读 | 创新药行业利好频传，和黄医药盘中大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107845235","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107845235?lang=zh_cn&edition=full","pubTime":"2026-03-30 14:03","pubTimestamp":1774850633,"startTime":"0","endTime":"0","summary":"和黄医药(00013)今日盘中大涨5.03%，表现突出。消息面上，据国家药监局数据显示，我国创新药行业近期发展迅猛。今年截至目前，创新药对外授权交易总额已超过600亿美元，接近2025年全年的一半。此外，2025年全年批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样刷新纪录。这些数据表明中国创新药研发实力与质量获得国际认可，行业前景乐观。作为创新药概念股之一，和黄医药在此行业整体利好消息的带动下，股价获得提振，盘中出现显著上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2e01cbc0eb24c402eed6076bf7c5c222","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678703","title":"部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623678703?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:23","pubTimestamp":1774837415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 部分创新药概念股逆市上扬，荣昌生物 涨4.99%，康方生物涨4.75%，诺诚健华涨3.66%，先声药业涨2.73%，远大医药涨2.65%，和黄医药涨1.37%。据人民日报从国家药监局获悉，今年截至目前，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。今年截至3月27日，我国共批准上市10款创新药，其中8款是中国原创新药。2025年，我国批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样创历史新高。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1161","LU1064130708.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0417516902.SGD","LU2476274308.USD","LU0634319403.HKD","09995","IE00BPRC5H50.USD","LU1794554557.SGD","LU1969619763.USD","BK1574","IE00B5MMRT66.SGD","BK1191","LU0348825331.USD","02096","LU2476274720.SGD","LU0348766576.USD","LU0561508036.HKD","LU0348767384.USD","LU2488822045.USD","LU0417516571.SGD","LU1064131003.USD","LU2399975544.HKD","LU0348784397.USD","LU1961090484.USD","06978","09926","159992","00512","BK1588","BK1587","LU0417516738.SGD","LU0348735423.USD","LU2148510915.USD","00013","09969","LU1720050803.USD","688331","LU2778985437.USD","LU0348827113.USD","BK1583","LU0348783233.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621747577","title":"和黄医药(00013)启动HMPL-760用于治疗复发/难治性弥漫性大B细胞淋巴瘤的中国III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747577","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621747577?lang=zh_cn&edition=full","pubTime":"2026-03-23 08:08","pubTimestamp":1774224537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，本公司今日宣布在中国启动HMPL-760联合R-GemOx 方案用于治疗复发/难治性弥漫性大 B细胞淋巴瘤患者的注册性III期临床试验。该研究是一项随机、双盲、阳性对照的III期临床研究，旨在评估HMPL-760联合R-GemOx方案对比安慰剂联合RGemOx方案用于治疗既往接受过一线系统化疗、免疫治疗或免疫化疗联合治疗后复发或难治性且不适合移植的弥漫性大B细胞淋巴瘤患者的疗效、安全性和药代动力学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","BK1191","BK4531","BK1588","BK4585","HCM","BK4007","III","BK4588","BK1587","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164777959","title":"和黄医药在中国启动HMPL-760治疗复发/难治性弥漫性大B细胞淋巴瘤的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1164777959","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164777959?lang=zh_cn&edition=full","pubTime":"2026-03-23 08:01","pubTimestamp":1774224085,"startTime":"0","endTime":"0","summary":"和黄医药（HUTCHMED）近日宣布，已在中国正式启动HMPL-760针对复发或难治性弥漫性大B细胞淋巴瘤患者的III期临床试验。该试验旨在评估这一创新疗法在特定患者群体中的安全性和有效性，标志着公司在该疾病领域研发的重要进展。\n弥漫性大B细胞淋巴瘤作为常见的恶性淋巴瘤类型，其复发或难治病例的治疗选择有限，临床需求迫切。此次III期试验的开展，有望为患者提供新的潜在治疗方向，并进一步巩固和黄医药在肿瘤创新药物研发领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1588","00013","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618800971","title":"和黄医药03月12日遭主力抛售369.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618800971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618800971?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:15","pubTimestamp":1773303343,"startTime":"0","endTime":"0","summary":"03月12日, 和黄医药股价跌1.23%，报收22.52元，成交金额7809.5万元，换手率0.40%，振幅3.77%，量比0.52。和黄医药今日主力资金净流出369.6万元，连续3日净流出，上一交易日主力净流出2462.1万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为62.50%，平均跌幅为2.94%。该股近5个交易日上涨7.12%，主力资金累计净流出1800.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出980.5万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312161852a4636647&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312161852a4636647&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1587","BK1588","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618890662","title":"中金：维持和黄医药(00013)跑赢行业评级 目标价30港币","url":"https://stock-news.laohu8.com/highlight/detail?id=2618890662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618890662?lang=zh_cn&edition=full","pubTime":"2026-03-12 10:26","pubTimestamp":1773282385,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑到和黄医药营运效率和盈利能力不断提高，上调2026年净利润预测59%至5,539万美元，引入2027年净利润预测8,891万美元。该行维持跑赢行业评级，基于DCF模型，维持目标价30港币不变，较当前股价有36.5%的上行空间。中金主要观点如下：2025年业绩符合该行预期公司公布2025业绩：收入5.49亿美元，同比-13%;其中肿瘤免疫板块综合收入2.85亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618978192","title":"每日卖空追踪 | 和黄医药 03月11日卖空量成交32.7万股，卖空比例为4.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618978192","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618978192?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217809,"startTime":"0","endTime":"0","summary":"和黄医药北京时间03月11日，涨3.73%，卖空量成交32.7万股，较上一交易日减少60.51%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163023a6b791d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163023a6b791d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1191","BK1588","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618110978","title":"获批仅一年即全球撤市，和黄医药达唯珂 ®黯然退场","url":"https://stock-news.laohu8.com/highlight/detail?id=2618110978","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618110978?lang=zh_cn&edition=full","pubTime":"2026-03-11 12:09","pubTimestamp":1773202140,"startTime":"0","endTime":"0","summary":"3月9日晚，和黄医药宣布在中国内地、香港及澳门启动达唯珂撤市及召回程序，并停止所有在研临床试验。达唯珂作为全球首创EZH2甲基转移酶抑制剂，2025年3月获国家药监局附条件批准用于治疗滤泡性淋巴瘤，是和黄医药首款商业化血液肿瘤药物，商业化进程中表现亮眼，销售额增幅高达158%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311121037a4602338&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311121037a4602338&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1191","BK1587","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618109952","title":"紧急召回！和黄医药明星抗癌药突遭撤市","url":"https://stock-news.laohu8.com/highlight/detail?id=2618109952","media":"深圳商报·读创","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618109952?lang=zh_cn&edition=full","pubTime":"2026-03-11 00:06","pubTimestamp":1773158781,"startTime":"0","endTime":"0","summary":"3月9日，和黄医药（中国）有限公司（简称“和黄医药”或“本公司”）发布公告，宣布对旗下上市仅满一年的肿瘤创新药他泽司他（商品名：达唯珂?）启动在中国内地、中国香港和中国澳门撤市并召回该产品，同时停止所有正在进行中的他泽司他的临床试验。现有患者应立即咨询主治医生，以讨论治疗选择。公告称，此次撤市预计不会影响本公司的财务指引。2025年，和黄医药的达唯珂?的销售额为250万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113667856575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1588","00013","HCM","BK4585","BK4007","BK1587","BK4588","BK1191","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618954412","title":"当年报披露遭遇商业化品种撤市，和黄医药(00013)何时打破“200亿估值魔咒”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618954412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618954412?lang=zh_cn&edition=full","pubTime":"2026-03-10 23:27","pubTimestamp":1773156440,"startTime":"0","endTime":"0","summary":"3月5日，和黄医药披露公司2025年年报业绩，其中公司当期股东应占溢利同比增长1111.03%，表现亮眼。根据财报，在和黄医药当期的4.57亿美元净利润中，有4.16亿美元来自出售上海和黄药业45%股权带来的收益。交易完成后，和黄医药仅持有上海和黄药业5%的股权。而在同一时间，现有品种的撤市，或许成为影响和黄医药估值的一个利空因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4531","BK4588","BK4585","BK1191","00013","BK1588","BK1587","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618333029","title":"华源证券：维持和黄医药(00013)“买入”评级 ATTC平台管线潜力可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2618333029","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618333029?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:42","pubTimestamp":1773132163,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华源证券发布研报称，预计和黄医药2026-2028年公司总收入为6.32、7.71、8.90亿美元。公司海外商业化进展稳健，ATTC平台管线潜力可期，维持公司“买入”评级。华源证券主要观点如下：事件2026年3月5日，和黄医药公布2025年全年业绩：2025年全年，公司营业总收入为5.49亿美元，同比下降12.96%；公司净利润为4.57亿美元，同比增长1111.03%。公司正积极寻求和跨国制药公司合作开发相关ATTC候选药物的潜在机会，未来可期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618987356","title":"【券商聚焦】交银国际维持和黄医药(00013)买入 指ATTC的潜在BD交易机会值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2618987356","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618987356?lang=zh_cn&edition=full","pubTime":"2026-03-10 15:47","pubTimestamp":1773128839,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指出，和黄医药 2025年产品销售在2H25如期实现复苏，全年实现可持续的盈利。2H25肿瘤产品收入呈现重要反弹趋势，环比1H25提升16%。全年实现净利润4.57亿美元，其中包含出售上海和黄药业45%股权所获得的税后收益4.16亿美元，剔除该一次性收益后，公司仍实现了可持续的盈利。该机构认为，随着更多临床前和早期临床数据逐步产生，ATTC的潜在BD交易机会值得期待。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976234","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03329","BK4585","BK1587","HCM","BK1191","00013","BK4007","BK4588","BK1588","BK4531","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618985668","title":"潜在风险可能已超过患者潜在获益，和黄医药紧急召回上市不足一年的抗癌新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2618985668","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618985668?lang=zh_cn&edition=full","pubTime":"2026-03-10 13:34","pubTimestamp":1773120854,"startTime":"0","endTime":"0","summary":"此次突发撤市、召回的导火索，源于该药的一项海外临床研究。根据益普生的通报，该研究的独立数据监察委员会在审查了SYMPHONY-1研究的最新数据后建议，基于继发性血液系统恶性肿瘤的不良事件，该治疗方案的潜在风险可能已超过患者的潜在获益。Epizyme为达唯珂在中国的药品上市许可持有人。虽然，和黄医药公告指出，此次撤市预计不会影响其财务指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773120681548363917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","BK4531","BK4585","BK4588","00013","HCM","BK1587","BK4007","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618360871","title":"和黄医药紧急宣布召回一款重磅肿瘤创新药；英硅智能与Liquid AI发布轻量科研基础模型 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2618360871","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618360871?lang=zh_cn&edition=full","pubTime":"2026-03-10 07:09","pubTimestamp":1773097780,"startTime":"0","endTime":"0","summary":"｜2026年3月10日星期二｜NO.1和黄医药紧急宣布召回一款重磅肿瘤创新药3月9日晚间，和黄医药公告称，其氢溴酸他泽司他片（商品名：达唯珂）的合作方益普生（Ipsen）已通知和黄医药正在美国自愿撤市该药，因此已采取措施在中国启动撤市及产品召回程序。和黄医药已随即启动在内地、香港和澳门撤市并召回该产品，并停止所有正在进行中的达唯珂的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103666571762.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103666571762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00013","HCM","159938","09939","BK1588","BK1191","BK4531","159992","BK4588","BK1515","BK4585","BK4007","BK1161","06978","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618624731","title":"和黄医药引进抗癌药不足一年撤市召回：风险或超过获益 去年销售额250万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618624731","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618624731?lang=zh_cn&edition=full","pubTime":"2026-03-09 21:58","pubTimestamp":1773064734,"startTime":"0","endTime":"0","summary":"在国内附条件批准不到一年，和黄医药从外部引进的一款抗癌药启动撤市及召回程序，并在全国撤网，还被移出首版商保创新药目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603093666384183.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666384183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","BK1191","00013","HCM","BK4585","BK4588","BK4531","BK1588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129173130","title":"和黄医药宣布：益普生自愿在美国撤回Tazverik","url":"https://stock-news.laohu8.com/highlight/detail?id=1129173130","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129173130?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:35","pubTimestamp":1773048944,"startTime":"0","endTime":"0","summary":"和黄医药今日披露，其合作伙伴益普生已主动决定在美国市场撤回抗癌药物Tazverik的上市许可。这一商业决策将影响该药物在美国的后续销售与推广策略。\n作为Tazverik的研发方之一，和黄医药将持续关注此次撤回对全球市场布局的潜在影响，并评估相关合作条款的调整空间。公司表示将积极配合益普生完成后续流程，同时继续推进其他创新肿瘤药物的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","BK1588","BK1587","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618984644","title":"和黄医药(00013)：已启动达唯珂®撤市及产品召回程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2618984644","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618984644?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:34","pubTimestamp":1773048859,"startTime":"0","endTime":"0","summary":"益普生已通知和黄医药，其正在美国自愿撤市达唯珂。因此，已采取措施在中国启动撤市及产品召回程序。和记黄埔医药(上海)有限公司已随即启动在中国内地、中国香港和中国澳门撤市并召回该产品，并停止所有正在进行中的他泽司他的临床试验。在获悉该信息后，和记黄埔医药(上海)有限公司立即对此产品采取锁库措施，暂停全部销售和发货，并通知医疗机构停止处方及药房停止售卖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"和黄医药(00013)：已启动达唯珂®撤市及产品召回程序","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","BK1587","BK1588","BK4007","BK1191","00013","BK4531","HCM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188259266","title":"和黄医药宣布撤回泰泽凯®在大中华区市场并终止所有活跃临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1188259266","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188259266?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:31","pubTimestamp":1773048701,"startTime":"0","endTime":"0","summary":"和黄医药（HUTCHMED）已决定从中国大陆、香港及澳门市场全面撤回其肿瘤靶向药物Tazverik®（泰泽凯®）。此项商业决策与产品撤回同步，公司同时宣布将终止该药物所有正在进行的临床试验项目。此举标志着泰泽凯®在大中华区的临床开发与商业化进程暂告段落。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1191","BK1588","00013"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0948},{"period":"1month","weight":0.1124},{"period":"3month","weight":0.1251},{"period":"6month","weight":-0.0811},{"period":"1year","weight":-0.0632},{"period":"ytd","weight":0.1426}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.066388},{"month":2,"riseRate":0.6,"avgChangeRate":0.075835},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093928},{"month":4,"riseRate":0.6,"avgChangeRate":0.032172},{"month":5,"riseRate":0,"avgChangeRate":-0.153959},{"month":6,"riseRate":0.5,"avgChangeRate":0.026468},{"month":7,"riseRate":1,"avgChangeRate":0.148281},{"month":8,"riseRate":0.2,"avgChangeRate":-0.0763},{"month":9,"riseRate":0.6,"avgChangeRate":-0.004654},{"month":10,"riseRate":0.2,"avgChangeRate":-0.040611},{"month":11,"riseRate":0.4,"avgChangeRate":0.13917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}